| scholarly article | Q13442814 |
| P356 | DOI | 10.1159/000336875 |
| P953 | full work available online at | http://www.karger.com/Article/Pdf/336875 |
| https://www.karger.com/Article/Pdf/336875 | ||
| P698 | PubMed publication ID | 22538523 |
| P50 | author | Matthias Ocker | Q39412202 |
| P2093 | author name string | M. Höpfner | |
| P2860 | cites work | Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor | Q22009126 |
| Understanding autophagy in cell death control. | Q37705544 | ||
| Integrating stress signals at the endoplasmic reticulum: The BCL-2 protein family rheostat. | Q37814626 | ||
| Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. | Q37834921 | ||
| Calcium and cell death mechanisms: a perspective from the cell death community | Q37860697 | ||
| Cetuximab in the treatment of patients with colorectal cancer | Q37873948 | ||
| Targeting the extrinsic apoptosis signaling pathway for cancer therapy | Q37882480 | ||
| The role of autophagy in cancer: therapeutic implications | Q37924056 | ||
| IAPs: guardians of RIPK1 | Q37957747 | ||
| Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. | Q38433102 | ||
| Overexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma | Q39467214 | ||
| Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis | Q39520993 | ||
| Prognostic significance of second mitochondria-derived activator of caspase (Smac/DIABLO) expression in bladder cancer and target for therapy | Q39685756 | ||
| Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types | Q39740467 | ||
| Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands | Q39755243 | ||
| Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression. | Q39774780 | ||
| Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress | Q22010800 | ||
| Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta | Q22011091 | ||
| Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1 | Q22011167 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer | Q24292870 | ||
| Inhibition of ADP/ATP exchange in receptor-interacting protein-mediated necrosis | Q24306119 | ||
| Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c | Q24309066 | ||
| Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis | Q24310597 | ||
| Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade | Q24311006 | ||
| Cleavage of p21Cip1/Waf1 and p27Kip1 Mediates Apoptosis in Endothelial Cells through Activation of Cdk2: Role of a Caspase Cascade | Q24314554 | ||
| Inhibition of death receptor signals by cellular FLIP | Q24316446 | ||
| Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3 | Q24324482 | ||
| Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics | Q24564912 | ||
| Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy | Q24635408 | ||
| Caspase Cleavage of Keratin 18 and Reorganization of Intermediate Filaments during Epithelial Cell Apoptosis | Q24683768 | ||
| RIPK-dependent necrosis and its regulation by caspases: a mystery in five acts | Q27026600 | ||
| Crystal structure of the Bcl-XL-Beclin 1 peptide complex: Beclin 1 is a novel BH3-only protein | Q27643981 | ||
| Signal integration in the endoplasmic reticulum unfolded protein response | Q27860577 | ||
| Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery | Q27860586 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Perk is essential for translational regulation and cell survival during the unfolded protein response | Q28140062 | ||
| Cell death by mitotic catastrophe: a molecular definition | Q28255830 | ||
| Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease | Q28261987 | ||
| Regulation of cell death protease caspase-9 by phosphorylation | Q28288607 | ||
| Autophagy Inhibition Enhances Daunorubicin-Induced Apoptosis in K562 Cells | Q28478256 | ||
| Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death | Q28586301 | ||
| ER stress regulation of ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals | Q28646129 | ||
| The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation | Q29547396 | ||
| Regulation mechanisms and signaling pathways of autophagy | Q29547416 | ||
| An inhibitor of Bcl-2 family proteins induces regression of solid tumours | Q29547595 | ||
| Expression, Cellular Distribution, and Prognostic Relevance of TRAIL Receptors in Hepatocellular Carcinoma | Q39831266 | ||
| Hsp90 inhibitors, GA and 17AAG, lead to ER stress-induced apoptosis in rat histiocytoma | Q39847843 | ||
| A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes | Q40008373 | ||
| Fenretinide induces autophagic cell death in caspase-defective breast cancer cells. | Q40015336 | ||
| Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis | Q40036325 | ||
| Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer | Q40126331 | ||
| The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells | Q40131236 | ||
| bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells | Q40155540 | ||
| Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model | Q40191245 | ||
| Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells | Q40339637 | ||
| Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer | Q40359028 | ||
| Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer | Q40385543 | ||
| Chemosensitisation of malignant melanoma by BCL2 antisense therapy | Q40611574 | ||
| The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant | Q41723645 | ||
| Deacetylase inhibitors - focus on non-histone targets and effects | Q41808915 | ||
| Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer | Q42628781 | ||
| Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases | Q42657216 | ||
| Ras is involved in the negative control of autophagy through the class I PI3-kinase | Q42830028 | ||
| Phase I/II Study of AT-101 with Topotecan in Relapsed and Refractory Small Cell Lung Cancer | Q42920935 | ||
| Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. | Q43711065 | ||
| Preliminary phase I results of G3139 (-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer | Q43784117 | ||
| BAD and Bcl-2 regulation are early events linking neuronal endoplasmic reticulum stress to mitochondria-mediated apoptosis | Q44280749 | ||
| Apoptosis Generates Stable Fragments of Human Type I Keratins | Q44865350 | ||
| Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models | Q46321841 | ||
| Correlation between loss of Bcl-XL expression and improved prognosis in advanced esophageal cancer treated by preoperative chemoradiotherapy | Q46518931 | ||
| Programmed cell death of developing mammalian neurons after genetic deletion of caspases. | Q48829797 | ||
| A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies | Q51700126 | ||
| CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme | Q53337288 | ||
| The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo | Q53406707 | ||
| Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study | Q56778458 | ||
| Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers | Q57694014 | ||
| Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer | Q63444329 | ||
| Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy | Q80624789 | ||
| Prognostic impact of bcl-2 expression on advanced nasopharyngeal carcinoma | Q81167339 | ||
| A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies | Q82847250 | ||
| Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors | Q82906878 | ||
| Necroptosis: a specialized pathway of programmed necrosis | Q83093772 | ||
| Correlation of Smac/DIABLO protein expression with the clinico-pathological features of breast cancer patients | Q84537482 | ||
| Expression of apoptosis-related proteins and its clinical implication in surgically resected gastric carcinoma | Q84987698 | ||
| A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors | Q85196462 | ||
| The pathophysiology of mitochondrial cell death | Q29547893 | ||
| The Bcl2 family: regulators of the cellular life-or-death switch | Q29614982 | ||
| Molecular mechanisms of necroptosis: an ordered cellular explosion | Q29616004 | ||
| Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury | Q29616008 | ||
| Eaten alive: a history of macroautophagy | Q29617841 | ||
| Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes | Q29620366 | ||
| BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis | Q29620466 | ||
| Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer | Q33338630 | ||
| Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia | Q33374227 | ||
| Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study | Q33385642 | ||
| Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors | Q33392841 | ||
| Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity | Q33392920 | ||
| Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors | Q33393931 | ||
| A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer | Q33395544 | ||
| Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer | Q33397708 | ||
| Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. | Q33435646 | ||
| Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors | Q33618126 | ||
| Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells | Q33632727 | ||
| Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer | Q33658593 | ||
| Serial killers: ordering caspase activation events in apoptosis | Q33782499 | ||
| Safety and antitumor activity of recombinant soluble Apo2 ligand | Q33855449 | ||
| Structure of an apoptosome-procaspase-9 CARD complex. | Q33869703 | ||
| Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5) | Q33906524 | ||
| Corpse clearance defines the meaning of cell death | Q33922730 | ||
| Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. | Q33941102 | ||
| The death domain superfamily in intracellular signaling of apoptosis and inflammation | Q33996534 | ||
| Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials | Q34032864 | ||
| Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial | Q34041573 | ||
| A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. | Q34155620 | ||
| Tumor necrosis factor signaling. | Q34185821 | ||
| The mitochondrion in apoptosis: how Pandora's box opens | Q34286386 | ||
| Signal transduction by tumor necrosis factor and its relatives | Q34341941 | ||
| Death by design: apoptosis, necrosis and autophagy | Q34365753 | ||
| Molecular mechanisms of drug resistance | Q34382998 | ||
| Everolimus for advanced pancreatic neuroendocrine tumors. | Q34399809 | ||
| Organelle-specific initiation of cell death pathways | Q34443559 | ||
| Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis | Q34451533 | ||
| Molecular steps of death receptor and mitochondrial pathways of apoptosis | Q34471764 | ||
| Cleavage of DFF-45/ICAD by multiple caspases is essential for its function during apoptosis | Q34476760 | ||
| New insights into the mechanisms of macroautophagy in mammalian cells | Q34785831 | ||
| Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin | Q34871780 | ||
| Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway | Q34910947 | ||
| The CD95(APO-1/Fas) DISC and beyond | Q35091401 | ||
| Autophagy promotes necrosis in apoptosis-deficient cells in response to ER stress | Q35120044 | ||
| Resistance mechanisms of gastrointestinal cancers: why does conventional chemotherapy fail? | Q35139963 | ||
| Survivin and IAP proteins in cell-death mechanisms | Q35414780 | ||
| A decade of caspases | Q35591686 | ||
| Prognostic role of sensitive-to-apoptosis gene expression in rectal cancer | Q35606935 | ||
| Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis. | Q35917233 | ||
| Overview of cell death signaling pathways | Q36051647 | ||
| Autophagy: dual roles in life and death? | Q36146947 | ||
| Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region | Q36784690 | ||
| Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma | Q36988067 | ||
| The roles of therapy-induced autophagy and necrosis in cancer treatment | Q37038235 | ||
| Inhibitor of apoptosis proteins and apoptosis | Q37134050 | ||
| Death through a tragedy: mitotic catastrophe | Q37135368 | ||
| Expansion and evolution of cell death programmes | Q37139298 | ||
| To kill a tumor cell: the potential of proapoptotic receptor agonists | Q37181734 | ||
| Anoikis resistance and tumor metastasis | Q37199998 | ||
| Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia | Q37355664 | ||
| Autophagy-A double-edged sword in oncology | Q37487968 | ||
| Smac mimetics as new cancer therapeutics. | Q37529027 | ||
| BH3-only proteins and their roles in programmed cell death | Q37566201 | ||
| Mimicking the BH3 domain to kill cancer cells | Q37566211 | ||
| 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen | Q37659067 | ||
| Death receptor agonists as a targeted therapy for cancer | Q37701624 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | apoptotic process | Q14599311 |
| P304 | page(s) | 111-120 | |
| P577 | publication date | 2012-04-24 | |
| P1433 | published in | European Surgical Research | Q15755712 |
| P1476 | title | Apoptosis-modulating drugs for improved cancer therapy | |
| Apoptosis-Modulating Drugs for Improved Cancer Therapy | |||
| P478 | volume | 48 |
| Q59803910 | (L.) P. Royen Leaf Water Extract Induces Apoptosis in Human Hepatocellular Carcinoma (HepG2) Cells via ERK1/2/Akt1/JNK1 Signaling Pathways |
| Q37549465 | A JNK-mediated autophagy pathway that triggers c-IAP degradation and necroptosis for anticancer chemotherapy. |
| Q34434902 | A signaling pathway consisting of miR-551b, catalase and MUC1 contributes to acquired apoptosis resistance and chemoresistance |
| Q35225941 | Annona muricata leaves induced apoptosis in A549 cells through mitochondrial-mediated pathway and involvement of NF-κB. |
| Q38829473 | Autophagy-Mediated Degradation of IAPs and c-FLIP(L) Potentiates Apoptosis Induced by Combination of TRAIL and Chal-24. |
| Q28547418 | Chemopreventive Activity of Ferulago angulate against Breast Tumor in Rats and the Apoptotic Effect of Polycerasoidin in MCF7 Cells: A Bioassay-Guided Approach |
| Q39052460 | Choline kinase inhibition induces exacerbated endoplasmic reticulum stress and triggers apoptosis via CHOP in cancer cells. |
| Q35895346 | Combination of the Deacetylase Inhibitor Panobinostat and the Multi-Kinase Inhibitor Sorafenib for the Treatment of Metastatic Hepatocellular Carcinoma - Review of the Underlying Molecular Mechanisms and First Case Report |
| Q28542976 | Compound A398, a novel podophyllotoxin analogue: cytotoxicity and induction of apoptosis in human leukemia cells |
| Q41901385 | Curcuma purpurascens BI. rhizome accelerates rat excisional wound healing: involvement of Hsp70/Bax proteins, antioxidant defense, and angiogenesis activity |
| Q33566824 | Enhancement of TRAIL-induced apoptosis by 5-fluorouracil requires activating Bax and p53 pathways in TRAIL-resistant lung cancers |
| Q92323815 | Epigenetic Regulation of RIP3 Suppresses Necroptosis and Increases Resistance to Chemotherapy in NonSmall Cell Lung Cancer |
| Q34340053 | Evaluation of acute toxicity and gastroprotective activity of curcuma purpurascens BI. rhizome against ethanol-induced gastric mucosal injury in rats |
| Q34265539 | Ferulago angulata activates intrinsic pathway of apoptosis in MCF-7 cells associated with G1 cell cycle arrest via involvement of p21/p27 |
| Q34446249 | Gastroprotective activity of Annona muricata leaves against ethanol-induced gastric injury in rats via Hsp70/Bax involvement |
| Q34867480 | Growth arrest and apoptosis via caspase activation of dioscoreanone in human non-small-cell lung cancer A549 cells |
| Q51145853 | Hinokitiol Inhibits Migration of A549 Lung Cancer Cells via Suppression of MMPs and Induction of Antioxidant Enzymes and Apoptosis |
| Q90298721 | Identification of proteins interacting with pORF5 in the pathogenesis of C. trachomatis |
| Q38086861 | Impact of EBV essential nuclear protein EBNA-3C on B-cell proliferation and apoptosis |
| Q37225564 | In vitro and in vivo anti-tumor activity of CoQ0 against melanoma cells: inhibition of metastasis and induction of cell-cycle arrest and apoptosis through modulation of Wnt/β-catenin signaling pathways |
| Q35068223 | Inhibitory effect of Curcuma purpurascens BI. rhizome on HT-29 colon cancer cells through mitochondrial-dependent apoptosis pathway |
| Q43185759 | Mechanisms of Drug Resistance in Veterinary Oncology- A Review with an Emphasis on Canine Lymphoma |
| Q28553543 | Monobenzyltin Complex C1 Induces Apoptosis in MCF-7 Breast Cancer Cells through the Intrinsic Signaling Pathway and through the Targeting of MCF-7-Derived Breast Cancer Stem Cells via the Wnt/β-Catenin Signaling Pathway |
| Q38262078 | Natural compounds to overcome cancer chemoresistance: toxicological and clinical issues |
| Q84957647 | Necroptosis and -Mediated Apoptosis of Astrocytes and Neurons, but Not Microglia, of Rat Hippocampus and Parenchyma Caused by Infection |
| Q35914434 | Pachymic acid induces apoptosis via activating ROS-dependent JNK and ER stress pathways in lung cancer cells |
| Q38906725 | Paraoxonase-2 (PON2) protects oral squamous cell cancer cells against irradiation-induced apoptosis |
| Q50797418 | Pentoxifylline during steroid window phase at induction to remission increases apoptosis in childhood with acute lymphoblastic leukemia. |
| Q53524085 | Raman spectroscopy as an analytical tool for melanoma research. |
| Q37235341 | Reduction of myeloid-derived suppressor cells and lymphoma growth by a natural triterpenoid. |
| Q38993971 | Role of Bax/Bcl-2 family members in green tea polyphenol induced necroptosis of p53-deficient Hep3B cells |
| Q41694174 | Selective cytotoxicity of vanadium complexes on human pancreatic ductal adenocarcinoma cell line by inducing necroptosis, apoptosis and mitotic catastrophe process. |
| Q35176405 | Synergistic anticancer effect of cisplatin and Chal-24 combination through IAP and c-FLIPL degradation, Ripoptosome formation and autophagy-mediated apoptosis |
| Q26821986 | Targeting caspases in cancer therapeutics |
| Q28546051 | The chemopotential effect of Annona muricata leaves against azoxymethane-induced colonic aberrant crypt foci in rats and the apoptotic effect of Acetogenin Annomuricin E in HT-29 cells: a bioassay-guided approach |
| Q35739508 | The chemopreventive potential of Curcuma purpurascens rhizome in reducing azoxymethane-induced aberrant crypt foci in rats |
| Q91415863 | Vasorin/ATIA Promotes Cigarette Smoke-Induced Transformation of Human Bronchial Epithelial Cells by Suppressing Autophagy-Mediated Apoptosis |
| Q48558923 | WITHDRAWN: Up-regulation of RIP3 alleviates cervical cancer progression through inducing necroptosis |
Search more.